Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
AGA Medical: Firm anticipates clearance of its Amplatzer Vascular Plug 4 in the third quarter after answering remaining questions from FDA on the application, AGA Medical CEO John Barr said during an Aug. 3 second quarter earnings call. He noted the questions are "not clinical in nature." The device, which has already launched in Europe, helped drive vascular plug sales up 51% in the quarter to $5.3 million. Corporate sales in the second quarter were $53.8 million, up 7.6% on a reported basis
You may also be interested in...
Regulatory News In Brief
Hologic panel: FDA's Radiological Devices Panel will weigh in on Hologic's Selenia Dimensions 3-D digital mammography tomosynthesis system on Sept. 24 in Gaithersburg, Md. The firm is seeking PMA approval for both screening and diagnostic indications. The panel is a long time in coming: the firm backed out of a June 2009 panel review to strengthen its case for the product, which it had originally hoped to launch in 2008. The firm most recently forecast approval late this year (1"The Gray Sheet" Feb. 8, 2010). The tomosynthesis technology is designed to address what Hologic calls the primary limitation of 2-D digital mammography, "namely, the superposition of normal breast anatomy that may mask a breast cancer.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.